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Effect of plasmapheresis on hyperviscosity-related retinopathy
and retinal hemodynamics in patients with Waldenström's
macroglobulinemia
Abstract
PURPOSE: Waldenström's macroglobulinemia (WM) is characterized by an overproduction of
immunoglobulin M (IgM), which can lead to a hyperviscosity syndrome (HVS) and HVS-related
retinopathy. Plasmapheresis is known to reduce serum viscosity (SV) and IgM levels. The purpose of
this study was to investigate the effects of plasmapheresis on HVS-related retinopathy and retinal
hemodynamic parameters in patients with WM. METHODS: Nine patients with HVS due to WM were
studied. SV and plasma IgM levels were measured before and after plasmapheresis treatment. The
patients were evaluated for HVS-related retinopathy, and hemodynamic changes in a major temporal
retinal vein by laser Doppler, before and after plasmapheresis. RESULTS: Plasmapheresis resulted in
significant reductions in serum IgM (46.5% +/- 18.0%, mean +/- SD; P = 0.0009) and SV (44.7% +/-
17.3%, P = 0.002). HVS-related retinopathy improved in all patients after plasmapheresis. After
treatment, the venous diameter decreased in each patient by an average of 15.3% +/- 5.8% (P = 0.0001).
A significant (P = 0.0004) 55.2% +/- 22.5% increase in retinal venous blood speed accompanied the
decreases in diameter. There was no significant change in the retinal blood flow rate after treatment. The
percentage decreases in SV in the patients were significantly correlated with the percentage decreases in
venous blood column diameter (P = 0.031, R(2) = 0.51). CONCLUSIONS: HVS triggers a distinctive
retinopathy with a central retinal vein occlusion (CRVO)-like appearance. However, the retinal blood
flow is not decreased as in CRVO, but remains at normal levels. Plasmapheresis is effective in reversing
HVS-related retinopathy and in reducing abnormal venous dilatation.
Effect of Plasmapheresis on Hyperviscosity-Related
Retinopathy and Retinal Hemodynamics in Patients
with Waldenstro¨m’s Macroglobulinemia
Marcel N. Menke,1,2,3 Gilbert T. Feke,1,2 J. Wallace McMeel,1,4 and Steven P. Treon5,6
PURPOSE. Waldenstro¨m’s macroglobulinemia (WM) is character-
ized by an overproduction of immunoglobulin M (IgM), which
can lead to a hyperviscosity syndrome (HVS) and HVS-related
retinopathy. Plasmapheresis is known to reduce serum vis-
cosity (SV) and IgM levels. The purpose of this study was to
investigate the effects of plasmapheresis on HVS-related
retinopathy and retinal hemodynamic parameters in patients
with WM.
METHODS. Nine patients with HVS due to WM were studied. SV
and plasma IgM levels were measured before and after plasma-
pheresis treatment. The patients were evaluated for HVS-re-
lated retinopathy, and hemodynamic changes in a major tem-
poral retinal vein by laser Doppler, before and after
plasmapheresis.
RESULTS. Plasmapheresis resulted in significant reductions in
serum IgM (46.5%  18.0%, mean  SD; P  0.0009) and SV
(44.7%  17.3%, P  0.002). HVS-related retinopathy im-
proved in all patients after plasmapheresis. After treatment, the
venous diameter decreased in each patient by an average of
15.3%  5.8% (P  0.0001). A significant (P  0.0004) 55.2%
 22.5% increase in retinal venous blood speed accompanied
the decreases in diameter. There was no significant change in
the retinal blood flow rate after treatment. The percentage
decreases in SV in the patients were significantly correlated
with the percentage decreases in venous blood column diam-
eter (P  0.031, R2  0.51).
CONCLUSIONS. HVS triggers a distinctive retinopathy with a cen-
tral retinal vein occlusion (CRVO)–like appearance. However,
the retinal blood flow is not decreased as in CRVO, but remains
at normal levels. Plasmapheresis is effective in reversing HVS-
related retinopathy and in reducing abnormal venous dilatation.
(Invest Ophthalmol Vis Sci. 2008;49:1157–1160) DOI:
10.1167/iovs.07-1254
Hyperviscosity syndrome (HVS) is a rare but severe disorderthat can accompany monoclonal and occasionally poly-
clonal paraproteinemias. HVS is especially caused by large
molecular compounds with a high intrinsic viscosity such as
IgM. Therefore, HVS is most frequent in Waldenstro¨m’s mac-
roglobulinemia (WM), a rare B-cell disorder characterized by
the production of monoclonal IgM.1,2 Symptoms associated
with HVS can be categorized as (1) general symptoms, such as
tiredness, fatigue, weight loss, and anorexia; (2) neurologic
symptoms, such as dizziness, vertigo, headaches, sudden hear-
ing loss, ataxia, and nausea; and (3) vascular disturbances, such
as retinopathy, epistaxis, gingival and gastrointestinal hemor-
rhages, nephropathy, and congestive heart failure.3,4
Historically, the symptoms associated with HVS had been
reported to occur at serum viscosity (SV) levels greater than 3
to 4 centipoise (cp).5,6 The normal range of SV is 1.2 to 1.8 cp.
However, our group recently reported7 that the initial mani-
festations of HVS-related retinopathy in WM can be seen in the
peripheral retina by using indirect ophthalmoscopy with
scleral depression in patients with SV levels as low as 2.1 cp
and IgM levels as low as 2950 mg/dL. In addition, we demon-
strated significant positive correlations between increasing ret-
inal arterial and venous diameters and increasing SV and IgM
levels.7
Plasmapheresis is the treatment of choice to attain signifi-
cant reduction of SV levels in patients with HVS. Because IgM
is a large molecule that remains 70% to 95% intravascular a
single plasmapheresis treatment can result in a reduction in
IgM levels of up to 42% with a decrease in SV of 48% to 60%.8,9
The purpose of this study was to examine the effect of plas-
mapheresis on HVS-related retinopathy and retinal hemody-
namics in patients with HVS due to WM.
METHODS
Nine patients (eight men and one woman, average age 59  9 years)
from the Dana Farber Cancer Institute (DFCI; Boston, MA), who had an
established diagnosis of WM, who had been positively tested for HVS,
and who were already scheduled for plasmapheresis as part of their
treatment regimen at DFCI, were studied.
Plasmapheresis was performed with a commercial system (Spectra
Apheresis System; COBE Laboratories, Lakewood, CO).10 The dual-
needle therapeutic plasma exchange (TPE) procedure was used in all
patients. During the procedure, anticoagulated whole blood enters the
system through an inlet tube. Separation of plasma from the cellular
blood components happens in the so-called TPE channel. A built-in
centrifuge facilitates the separation of blood components. As blood
flows through the TPE channel, cellular components move to the
outside of the channel, whereas the plasma remains on the inside of
the channel. Most plasma exits the channel through a “plasma-out”
tube into a plasma waste bag. The cellular components exit through a
separate pathway (the red blood cell return tube), to be returned to the
patient. This process ensures that the hematocrit remains unaltered
after treatment.
Immediately before plasmapheresis, the patients were evaluated for
HVS-related retinopathy. Each patient underwent a visual acuity test,
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intraocular pressure (IOP) check, slitlamp biomicroscopy, indirect
ophthalmoscopy with scleral depression, and fundus photography. In
addition, laser Doppler retinal blood flow testing (CLBF 100; Canon,
Inc., Tokyo, Japan) was performed in each patient on the major
superior or inferior temporal retinal veins in both eyes. Retinal venous
blood column diameter and centerline blood speed were measured
simultaneously, and the retinal blood flow rate was automatically
calculated at each measurement site.11 The same ophthalmic assess-
ments were repeated between 6 and 22 days after plasmapheresis
treatment. Patients remained on the same concomitant medication
regimens before and after plasmapheresis.
Follow-up laser Doppler measurement sites along retinal veins
were the same as the pretreatment sites. Results from the vein with the
largest blood column diameter measured before plasmapheresis in
each patient were used in the analysis. Brachial blood pressure, SV, and
plasma IgM levels were also measured before and after plasmapheresis.
All patients gave written informed consent to undergo the ophthalmic
procedures involved in the study and the ophthalmic protocol, ap-
proved by the Schepens Eye Research Institute institutional review
board, adhered to the guidelines of the Declaration of Helsinki.
The statistical significance of pre- and posttreatment comparisons
was assessed with paired t-tests. Pearson correlation coefficients be-
tween measured variables were determined by simple linear regression
analysis. P  0.05 was considered to be statistically significant. Results
are expressed as the mean  SD.
RESULTS
The serum IgM and SV levels measured in each patient before
and after plasmapheresis are shown in Figure 1. The average
reduction in serum IgM was 46.5%  18.0% (P  0.0009). The
average reduction in SV was 44.7% 17.3% (P 0.002). There
were significant decreases in both systolic (P  0.0047) and
diastolic (P  0.0023) brachial blood pressures (BP) after
plasmapheresis. On average, systolic BP decreased from 127 
17 to 117  16 mm Hg, and diastolic BP decreased from 65 
13 to 59  8 mm Hg. Before treatment, average Snellen visual
acuity was 20/30 (range, 20/15–20/70), and IOP was 13  4
mm Hg. There were no significant changes in visual acuity or
IOP after plasmapheresis.
Before plasmapheresis, slitlamp biomicroscopy and indirect
ophthalmoscopy revealed retinal findings typical in patients
with HVS. We found peripheral and central dot and blotlike
hemorrhages. Retinal veins were dilated and tortuous, showing
focal constrictions, predominantly at arteriovenous junctions
(venous sausaging). Optic disc edema was present in two
patients. After treatment, retinal appearance improved in all
patients, showing narrower retinal veins with less tortuosity,
fewer retinal hemorrhages, and decreased optic disc edema, if
initially present. Figure 2 shows fundus photographs of a pa-
tient before and after plasmapheresis.
The retinal venous blood column diameters measured in
each patient before and after plasmapheresis are shown in
Figure 3. Before plasmapheresis, the retinal veins were mark-
edly dilated, with an average diameter of 184  22 m. After
treatment, venous diameters decreased to 155  18 m (mean
reduction, 15.3%  5.8%, P  0.0001). A significant (P 
0.0004) 55.2%  22.5% increase in retinal venous blood speed
accompanied the decreases in diameter. Before treatment, ve-
nous blood speed was 19.0  3.3 mm/s; after treatment, blood
speed was 29.2  5.4 mm/s. As a result, there was no signifi-
cant change in retinal venous blood flow (12.3%  22.0%, P 
0.16). On average, the blood flow was 14.2  4.5 L/min
FIGURE 1. Serum IgM (A) and SV (B) levels measured in each patient
before and after plasmapheresis treatment.
FIGURE 2. Left: Before plasmaphere-
sis optic disc edema (arrowheads),
central retinal hemorrhages (bold ar-
rows), and venous “sausaging” (thin
arrows) were observed. Right: After
plasmapheresis disc edema and reti-
nal hemorrhages improved. Venous
sausaging disappeared.
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before treatment and 15.8  5.7 L/min after treatment. As
shown in Figure 4, the percentage decreases in SV after plas-
mapheresis correlated significantly with the accompanying
percentage deceases in retinal venous diameter (P  0.031, R2
 0.51).
DISCUSSION
Our patients showed significant reductions in SV and serum
IgM levels after plasmapheresis treatment. These reductions
were accompanied by a lessening of the severity of HVS-related
retinopathy. Our findings are in agreement with those in early
studies,12,13 showing that plasmapheresis is effective in revers-
ing HVS-related retinopathy in patients with WM.
The hemodynamic measurements showed significant reduc-
tions in venous diameter that were accompanied by significant
increases in venous blood speed after plasmapheresis. As a
result, the blood flow rate after treatment was not significantly
different from the pretreatment level. It is possible, however,
that the 11% increase in blood flow rate measured after treat-
ment may have been due to an underestimation of the blood
speed before treatment. The calculation of the blood flow rate
assumes a parabolic spatial profile of blood speeds in the
measured vessel.11 The elevated SV present before treatment
may have produced some blunting of the speed profile. After
treatment, with reduced SV, the profile most likely reverted to
its parabolic shape.
Other investigators14,15 had used video fluorescein angiog-
raphy to investigate the retinal circulation in patients with HVS
and found abnormally long arteriovenous passage times of the
dye tracer. This suggested a reduced blood speed in these
patients and perpetuated the supposition16 that HVS is a type
of venous stasis retinopathy that is also found in central retinal
vein occlusion. The results of our recently reported cross-
sectional study,7 however, showed that while dilated retinal
vessels and reduced blood speeds are indicative of HVS-related
retinopathy, the blood flow rate itself remains at a healthy
normal level. The results of our present study, reported herein,
also show that the blood flow rate remains essentially un-
changed during the reversal of HVS-related retinopathy.
Moreover, our results showed a significant correlation be-
tween the percentage decrease in SV levels and the percentage
decrease in retinal venous diameters after plasmapheresis. This
coupling between SV levels and retinal vessel diameters was
also shown in our prior study.7 Elevated SV increases the
vascular resistance to flow, whereas vascular dilatation de-
creases the resistance to flow. It appears that the retinal vas-
cular response to plasmapheresis is a vascular constriction of
just the appropriate magnitude to balance the change in resis-
tance caused by the decrease in SV. This result suggests that
the hemodynamic results that we have observed in patients
with WM and HVS are governed by a well functioning retinal
vascular autoregulation system.17
As we have suggested,7 in HVS, there is an active compen-
satory arterial and arteriolar dilation that results in higher local
intravascular pressures throughout the capillary network that
explains the occurrence of retinal hemorrhages. The elevated
pressures extend to the venous side of the vascular system and
explain the observed venous dilation.
A contributing factor to the observed venous dilation may
be hypervolemia, which frequently accompanies HVS.18 Plas-
mapheresis is known to reduce hypervolemia.19 The signifi-
cant decrease in the systolic and diastolic brachial blood pres-
sures after plasmapheresis may be related to the reduction in
hypervolemia.
In summary, hyperviscosity triggers a particular type of
retinopathy with retinal vein occlusion–like appearance. How-
ever, retinal blood flow remains at normal levels. Plasmaphere-
sis ameliorates HVS-related retinopathy and normalizes retinal
hemodynamics. Examination of the retina is useful in identify-
ing the symptomatic threshold of plasma viscosity levels in
patients with HVS and can be used to gauge the effectiveness
of plasmapheresis treatment.
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